Young MR - Search Results

1

A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits".

Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, Young MR, Colburn NH. Kang MI, et al. Among authors: young mr. Mol Cancer Ther. 2009 Mar;8(3):571-81. doi: 10.1158/1535-7163.MCT-08-0811. Epub 2009 Mar 3. Mol Cancer Ther. 2009. PMID: 19258426 Free PMC article.

2

Suppression of p65 phosphorylation coincides with inhibition of IkappaBalpha polyubiquitination and degradation.

Hu J, Haseebuddin M, Young M, Colburn NH. Hu J, et al. Mol Carcinog. 2005 Dec;44(4):274-84. doi: 10.1002/mc.20142. Mol Carcinog. 2005. PMID: 16163708

3

Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4.

Young MR, Yang HS, Colburn NH. Young MR, et al. Trends Mol Med. 2003 Jan;9(1):36-41. doi: 10.1016/s1471-4914(02)00009-6. Trends Mol Med. 2003. PMID: 12524209 Review.

4

Fra-1 a target for cancer prevention or intervention.

Young MR, Colburn NH. Young MR, et al. Gene. 2006 Sep 1;379:1-11. doi: 10.1016/j.gene.2006.05.001. Epub 2006 May 6. Gene. 2006. PMID: 16784822 Review.

5

A high-throughput cell-based assay to identify specific inhibitors of transcription factor AP-1.

Ruocco KM, Goncharova EI, Young MR, Colburn NH, McMahon JB, Henrich CJ. Ruocco KM, et al. Among authors: young mr. J Biomol Screen. 2007 Feb;12(1):133-9. doi: 10.1177/1087057106296686. Epub 2006 Dec 14. J Biomol Screen. 2007. PMID: 17175522

6

Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.

Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck GR Jr, Young MR, Colburn NH. Matthews CP, et al. Among authors: young mr. Cancer Res. 2007 Mar 15;67(6):2430-8. doi: 10.1158/0008-5472.CAN-06-0522. Cancer Res. 2007. PMID: 17363560

7

AP-1 a target for cancer prevention.

Matthews CP, Colburn NH, Young MR. Matthews CP, et al. Among authors: young mr. Curr Cancer Drug Targets. 2007 Jun;7(4):317-24. doi: 10.2174/156800907780809723. Curr Cancer Drug Targets. 2007. PMID: 17979626 Review.

8

Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation.

Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR, Colburn NH. Hsu TC, et al. Among authors: young mr. Cancer Res. 2001 May 15;61(10):4160-8. Cancer Res. 2001. PMID: 11358840

9

Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun.

Young MR, Farrell L, Lambert P, Awasthi P, Colburn NH. Young MR, et al. Mol Carcinog. 2002 Jun;34(2):72-7. doi: 10.1002/mc.10050. Mol Carcinog. 2002. PMID: 12112313

10

Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue?

Young MR, Santhanam AN, Yoshikawa N, Colburn NH. Young MR, et al. Mol Interv. 2010 Apr;10(2):76-9. doi: 10.1124/mi.10.2.5. Mol Interv. 2010. PMID: 20368367 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

428 results

Search Page

Filters